219,860 Shares in Pfizer Inc. $PFE Purchased by CTC Alternative Strategies Ltd.

Key Points

• CTC Alternative Strategies Ltd. acquired a new stake in Pfizer Inc. by purchasing 219,860 shares valued at approximately $5.57 million, which constitutes about 6.8% of their portfolio.
• Pfizer's stock performance shows a one-year range with a low of $20.92 and a high of $30.43, and the company's recent earnings report exceeded expectations with $0.78 EPS against an estimate of $0.58.
• Analysts maintain a consensus rating of "Hold" for Pfizer with a target price of $28.12, as several brokerages have recently adjusted their price targets upwards for the company.

CTC Alternative Strategies Ltd. bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 219,860 shares of the biopharmaceutical company's stock, valued at approximately $5,571,000. Pfizer comprises about 6.8% of CTC Alternative Strategies Ltd.'s investment portfolio, making the stock its 2nd largest holding.

Several other large investors also recently bought and sold shares of PFE. Pacer Advisors Inc. grew its position in Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock worth $508,164,000 after purchasing an additional 17,957,928 shares during the last quarter. Amundi grew its position in Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Nuveen LLC purchased a new stake in Pfizer during the 1st quarter worth approximately $389,861,000. Starboard Value LP purchased a new stake in Pfizer during the 4th quarter worth approximately $407,730,000. Finally, Goldman Sachs Group Inc. grew its position in Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock worth $670,407,000 after purchasing an additional 9,041,990 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

PFE has been the topic of several research analyst reports. Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Berenberg Bank dropped their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Morgan Stanley upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Jefferies Financial Group upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Finally, HSBC dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Stock Performance

NYSE PFE traded down $0.33 during mid-day trading on Monday, reaching $24.55. 49,188,016 shares of the stock were exchanged, compared to its average volume of 34,669,424. The business's 50 day moving average is $24.85 and its 200-day moving average is $24.32. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a market capitalization of $139.56 billion, a P/E ratio of 13.06, a P/E/G ratio of 0.88 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the prior year, the firm posted $0.60 earnings per share. The firm's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were issued a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer's dividend payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.